Cardiff Oncology, Inc.CRDFNASDAQ
Loading
ROE: Returns DecliningContracting
Percentile Rank43
Studio
Year-over-Year Change

Return on equity

Latest
-101.08%
↑ 20% vs avg
Percentile
P43
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-125.58%
Historical baseline
PeriodValueYoY Change
2025-101.08%-84.5%
2024-54.77%+7.8%
2023-59.42%-63.3%
2022-36.40%-80.6%
2021-20.15%-33.7%
2020-15.06%+93.3%
2019-224.50%-37.5%
2018-163.24%+57.4%
2017-382.83%-93.0%
2016-198.32%-